These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2216 related items for PubMed ID: 19661225

  • 1. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 3. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu W, Lin Y, Zhou Z, Qu J.
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [Abstract] [Full Text] [Related]

  • 4. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K, Rüden Jv, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ.
    Cancer Lett; 2010 Sep 01; 295(1):100-9. PubMed ID: 20356670
    [Abstract] [Full Text] [Related]

  • 5. L-leucine increases [3H]-thymidine incorporation in chicken hepatocytes: involvement of the PKC, PI3K/Akt, ERK1/2, and mTOR signaling pathways.
    Lee MY, Jo SD, Lee JH, Han HJ.
    J Cell Biochem; 2008 Dec 15; 105(6):1410-9. PubMed ID: 18980246
    [Abstract] [Full Text] [Related]

  • 6. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O, Almazan G.
    J Neurochem; 2009 Jun 15; 109(5):1440-51. PubMed ID: 19453943
    [Abstract] [Full Text] [Related]

  • 7. Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways.
    Lin SJ, Chang C, Ng AK, Wang SH, Li JJ, Hu CP.
    Apoptosis; 2007 Sep 15; 12(9):1659-70. PubMed ID: 17624592
    [Abstract] [Full Text] [Related]

  • 8. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Oncogene; 2010 Feb 04; 29(5):739-51. PubMed ID: 19881535
    [Abstract] [Full Text] [Related]

  • 9. High glucose regulates cyclin D1/E of human mesenchymal stem cells through TGF-beta1 expression via Ca2+/PKC/MAPKs and PI3K/Akt/mTOR signal pathways.
    Ryu JM, Lee MY, Yun SP, Han HJ.
    J Cell Physiol; 2010 Jul 04; 224(1):59-70. PubMed ID: 20232305
    [Abstract] [Full Text] [Related]

  • 10. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB.
    Endocr Relat Cancer; 2009 Dec 04; 16(4):1329-38. PubMed ID: 19620247
    [Abstract] [Full Text] [Related]

  • 11. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):830-8. PubMed ID: 20522531
    [Abstract] [Full Text] [Related]

  • 12. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D.
    Ann Clin Lab Sci; 2008 Sep 01; 38(3):195-209. PubMed ID: 18715846
    [Abstract] [Full Text] [Related]

  • 13. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 14. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Dalino P, Salahuddin N, Korbonits M, Grossman AB.
    Neuroendocrinology; 2008 Feb 05; 87(3):168-81. PubMed ID: 18025810
    [Abstract] [Full Text] [Related]

  • 15. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
    Xu Y, Chen SY, Ross KN, Balk SP.
    Cancer Res; 2006 Aug 01; 66(15):7783-92. PubMed ID: 16885382
    [Abstract] [Full Text] [Related]

  • 16. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH, Bohula EA, Macaulay VM.
    Oncogene; 2006 Oct 26; 25(50):6574-81. PubMed ID: 16715137
    [Abstract] [Full Text] [Related]

  • 17. Homocysteine induces smooth muscle cell proliferation through differential regulation of cyclins A and D1 expression.
    Chiang JK, Sung ML, Yu HR, Chang HI, Kuo HC, Tsai TC, Yen CK, Chen CN.
    J Cell Physiol; 2011 Apr 26; 226(4):1017-26. PubMed ID: 20857402
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 19. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.
    Expert Opin Investig Drugs; 2009 Sep 16; 18(9):1333-49. PubMed ID: 19678801
    [Abstract] [Full Text] [Related]

  • 20. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA.
    Cancer Res; 2005 Sep 01; 65(17):7800-8. PubMed ID: 16140948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 111.